| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.0 |
| Net income | -3.0 | -0.9 |
| EPS (diluted, $ a share) | $-3.53 | $-21.76 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DCOY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Decoy Therapeutics Inc.: key numbers
- Share price
- $0.9010Close, Nov 16
- Market cap
- $2.15M
- Shares outstanding
- 2.39MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Decoy Therapeutics Inc.
All →Decoy Therapeutics Capital Raise of $3.85M
Decoy Therapeutics entered into a warrant inducement agreement with an institutional investor for the immediate cash exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share. The transaction generated $3.85 million in gross proceeds and included the issuance of 2,368,868 new unregistered warrants to the holder. Proceeds are intended for working capital and general corporate purposes.
- Value
- $3.85M
- Counterparty
- institutional investor
Decoy Therapeutics Shareholder Meeting
Decoy Therapeutics held a Special Meeting of Stockholders on September 14, 2026, where shareholders approved the issuance of common stock upon the exercise of Series A, B, and C Milestone Warrants. Stockholders also approved an amendment to the Certificate of Incorporation to reduce the number of authorized shares of common stock from 100 million to 90 million.